• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • All Features
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Marico Ltd.
    09 Feb 2026
    770.65
    0.03%
    Marico to acquire 75% of Vietnam's Skinetiq in Rs 261 crore deal
    Marico to acquire 75% of Vietnam's Skinetiq in Rs 261 crore deal
    Economic Times
    Consumer goods company Marico is expanding its international presence. It has acquired a 75% stake in Vietnamese direct-to-consumer beauty firm Skinetiq. This move strengthens Marico's premium beauty portfolio and D2C strategy abroad. Vietnam is a key market for Marico due to its economic growth and evolving beauty sector. The company also recently acquired Indian plant-based protein brand Cosmix.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 1026 to 1049 in Dec 2025 qtr.
    Marico to acquire 75% stake in Vietnamese skincare start-up Skinetiq
    Business Line | 09 Feb 2026
    logo
    Zydus Wellness Ltd.
    09 Feb 2026
    406.55
    -1.79%
    Zydus Lifesciences Q3 net profit rises 9% on strong US and India growth
    Zydus Lifesciences Q3 net profit rises 9% on strong US and India growth
    Business Standard
    Zydus Lifesciences posted higher Q3 profit and revenue, aided by strong growth in the US and India businesses, improved margins, and steady momentum in generics, specialty and chronic segments
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. has an average target of 562.50 from 6 brokers.
    Zydus Lifesciences posts 30% revenue jump in Q3, net profit up 9%
    Business Line | 09 Feb 2026 2 more
    Zydus Life Q3 result: Profit up marginally at 1,042 cr, revenue jumps 32%
    Business Standard | 09 Feb 2026
    Zydus Life Q3 result: Profit up marginally at 1,042 cr, revenue jumps 32%
    Business Standard | 09 Feb 2026
    logo
    Jyothy Labs Ltd.
    09 Feb 2026
    248.32
    -1.80%
    Jyothy Labs reports 5.1% revenue growth in Q3, volume up 7.2%
    Business Line
    The Fabric Care segment led the performance with 9.2 per cent value growth in Q3, driven by strong momentum in liquid detergents across brands including Ujala, Henko, Mr. White and Morelight
    Copy LinkShare onShare on Share on Share on
    Jyothy Labs Ltd. has an average target of 344.20 from 6 brokers.
    logo
    Britannia Industries Ltd.
    09 Feb 2026
    Rising Profit
    6102.00
    1.38%
    Britannia Q3 preview: Profit may rise 18%; margins, volumes to improve
    Business Standard
    Britannia Q3 results preview: Brokerages tracked by Business Standard estimate Britannia's net profit to average 687 crore, compared to 581.7 crore a year ago, up 18 per cent year-on-year (Y-o-Y)
    Copy LinkShare onShare on Share on Share on
    Britannia Industries.. has an average target of 6554.29 from 7 brokers.
    logo
    Zydus Wellness Ltd.
    06 Feb 2026
    406.55
    -1.79%
    Zydus receives orphan drug status for Sickle Cell Disease medication
    Business Standard
    Zydus Lifesciences on Friday said the US health regulator has granted Orphan Drug Designation to Desidustat, a novel oral product medication for the treatment of Sickle Cell Disease. The US Food and Drugs Administration's (USFDA) grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 2 lakh people in the US. "This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease. We believe that Desidustat can address this unmet need," Zydus Lifesciences MD Sharvil Patel said in a statement. Therapeutic options for management of Sickle Cell Disease are currently limited. A Phase II, double blind, randomised, placebo controlled, parallel, multi-centre, proof-of-concept study to evaluate the efficacy and safety of Desidustat oral tablet for treatment of SCD has been completed, and data will be published in a medical journal, the drug firm said. Orphan drug designation by
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. has an average target of 562.50 from 6 brokers.
    logo
    Hindustan Unilever Ltd.
    05 Feb 2026
    Estimates Beat
    2409.70
    -2.16%
    WOTR, Hindustan Unilever Foundation launch water, farming programme in Gadchiroli
    Business Line
    The programme is projected to generate additional community income of about 15.12 crore.
    Copy LinkShare onShare on Share on Share on
    Hindustan Unilever Ltd.'s price crossed below 100Day SMA today
    logo
    Emami Ltd.
    05 Feb 2026
    495.35
    -1.11%
    Broker's Call: Emami (Buy)
    Business Line
    Asit C Mehta Investment
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 304 to 278 in Dec 2025 qtr
    Emami shares gain 5% on in-line Q3 results; stock targets revised higher
    Business Standard | 05 Feb 2026 1 more
    Emami Q3 net up 14.5% at 319.5 crore, revenue rises 9.7%
    Business Line | 04 Feb 2026
    logo
    Marico Ltd.
    04 Feb 2026
    770.65
    0.03%
    Marico To Acquire 60% Stake In Cosmix Wellness For Rs 226 Crore
    NDTV Profit
    The firm will acquire 60% of Cosmix Wellness paid-up share capital via secondary buy-out.
    Copy LinkShare onShare on Share on Share on
    ICICI Direct released a Buy report for Marico Ltd. with a price target of 870.0 on 29 Jan, 2026.
    Marico signs deal to buy majority stake in Cosmix Wellness for 225.67 cr
    Business Standard | 04 Feb 2026 1 more
    Marico acquires 60% stake in wellness brand Cosmix for 375 crore
    Business Line | 04 Feb 2026
    logo
    Zydus Wellness Ltd.
    04 Feb 2026
    406.55
    -1.79%
    Zydus Lifesciences gets US FDA approval for generic diabetes drug
    Business Standard
    Zydus Lifesciences on Wednesday has received approval from the US health regulator to market a generic diabetes drug in the US market. The company has received tentative approval from the US Food and Drug Administration (USFDA) for Dapagliflozin Tablets in strengths of 5 mg and 10 mg, the drug firm said in a statement. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. The company said the tablets will be manufactured at its formulation manufacturing facility at SEZ, Ahmedabad. As per the industry estimates, Dapagliflozin tablets had annual sales of USD 10,486.9 million in the US. Zydus shares on Wednesday ended 0.23 per cent up at Rs 905 apiece on BSE.
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. has an average target of 562.50 from 6 brokers.
    logo
    Zydus Wellness Ltd.
    04 Feb 2026
    406.55
    -1.79%
    Zydus Wellness Q3 Review: Anand Rathi Stays 'Buy' Despite Mixed Numbers Check Revised Target Price
    NDTV Profit
    Zydus Wellness delivered a mixed set of numbers in Q3, with healthy double-digit organic volume growth driving revenue to Rs 960 crore.
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. has an average target of 562.50 from 6 brokers.
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    • All Features
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • Marushika Technology
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2026 Giskard Datatech Pvt Ltd (RA SEBI Reg No: INH000022507)